GlassScriptPhysician profile
April Blad Schmit
NPI 1144704370
$2,694.68
in general payments reported to CMS, 2019-2025
11 companies · $1,919 in 2025
The $1,919 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.19 · 2022: $37.42 · 2023: $243 · 2024: $483 · 2025: $1,919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729 · Travel and Lodging: $818 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.57 |
| Travel and Lodging | $817.51 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,703.18 | 2023-2025 | Inspire |
| Harmony Biosciences LLC | $643.74 | 2023-2025 | Wakix |
| Avadel Cns Pharmaceuticals, LLC | $72.44 | 2025 | Lumryz |
| Boston Scientific Corporation | $48.61 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $44.05 | 2024-2025 | Horizant |
| Axsome Therapeutics, INC. | $38.29 | 2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $35.47 | 2024 | |
| Idorsia Pharmaceuticals US INC | $35.45 | 2024 | Quviviq |
| Resmed Corp | $34.62 | 2023-2024 | |
| Lilly USA, LLC | $21.42 | 2025 | Zepbound |
| Zoll Respicardia, INC. | $17.41 | 2024 | Remede System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Schmit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.